Microbiological and Immunological Studies on COVID-19 Patients | ||
| Mansoura Journal of Biology | ||
| Volume 58, Issue 5, December 2022, Pages 1-5 PDF (834.28 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mjb.2022.456299 | ||
| Authors | ||
| Al-Guburi Ali Abdulkareem* 1; Gamal M. Abdel-Fattah1; Hewidy Asem Abdelhamid2; Heba Elsayed Abdelmonem Eldegla3 | ||
| 1Department of Botany, Faculty of Science, Mansoura University, Mansoura, Egypt. | ||
| 2Isolation University Hospital, Faculty of Medicine, Mansoura University. | ||
| 3Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. | ||
| Abstract | ||
| The coronavirus disease-2019 (COVID-19) epidemic has triggered a worldwide epidemic. Critical breathing pain disease (ARDS) and multiorgan failure are two of the most common reasons of passing in COVID-19-infected disapprovingly sick patients. The increased seditious cytokines propose that a cytokines storm, also known as cytokine release syndromes (CRS), may be complicated in COVID-19 pathogenesis. However, the effectiveness of corticosteroids, which are routinely used anti-inflammatory drugs, in treating COVID-19-induced CRS is debatable. Novel treatments for COVID-19-induced CRS are desperately needed. we describe the pathophysiology of SARS-induced CRS, compare COVID-19 CRS to SARS and Middle East living sickness (MERS), and review current CRS therapeutics. We propose using interleukin-6 (IL-6) inhibition to treat COVID-19-induced CRS. | ||
| Keywords | ||
| Microbiological; Immunological; Study On Covid-19 patients | ||
|
Statistics Article View: 2 |
||
